$MSOS

MSOS, TRLV Slide After Hours As DEA Judge Pauses Cannabis Rescheduling Case

MSOS, an ETF, and TRLV, one of its holdings, fell about 8-9% after hours as a federal judge paused a cannabis rescheduling case. The delay impacts investors' expectations for near-term changes to marijuana's legal status, which could affect the industry.

Original reporting
Published Sep 29, 2026, 11:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 12:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$MSOS
Bearish
high confidence
Mentioned
$MSOS · $TRLV
Relevance
7/10
AlphAI data visualization · based on stocktwits.com
Decision brief

The 30-second read

$MSOSBearishHigh
01

Why it matters

The decision removes near‑term regulatory upside, prompting immediate sell pressure in both the ETF (MSOS) and its top holding (TRLV).

02

Market read

Regulatory delay creates short‑term downside for cannabis‑related equities, with broader sector implications.

03

What to watch

Potential for future FDA‑approved products to move to Schedule III could still support the sector despite the current delay.

Relevance 7/10Novelty 8/10Timing: after-hours today

Background

A DEA chief judge halted a pending case to reclassify marijuana from Schedule I to Schedule III, delaying a catalyst that had been expected to boost cannabis stocks and ETFs.

Company-level read

Ticker impact

$MSOSBearishHigh confidence
Context

MSOS fell about 8% after hours as the DEA judge paused the cannabis rescheduling case, removing a near‑term catalyst.

Expected impact

likely pressure as the market prices in the rescheduling delay

Evidence & confidence

The ETF’s largest holding, TRLV, also dropped sharply; the news removes a catalyst that had been priced in.

$TRLVBearishHigh confidence
Context

Trulieve Cannabis dropped roughly 9% in extended trading after the DEA judge paused the case, despite a modest gain in regular session.

Expected impact

likely pressure as investors adjust to the delayed rescheduling decision

Evidence & confidence

The stock’s after‑hours decline mirrors the ETF’s move and reflects the same regulatory uncertainty.

Market effects

Cannabis sector sentiment weakened as a key regulatory catalyst was delayed.

U.S. market participants are most affected; the news is U.S.-centric.

Limited global impact beyond U.S. cannabis equities and ETFs.

Counterpoint

The pause may be temporary; investors could view the dip as a buying opportunity if rescheduling eventually proceeds.

Key entities

  • AdvisorShares Pure US Cannabis ETF

    Ticker MSOS, tracks U.S. cannabis equities.

  • Trulieve Cannabis Corp.

    Ticker TRLV, a leading U.S. medical and adult‑use cannabis operator.

  • DEA Chief Judge Derek Julius

    Paused the rescheduling case, affecting market expectations.

Related articles

$TRLVMed

Trulieve Cannabis (TRLV) Is Up 6.5% After ESOP-Linked US$55.5 Million Share Issuance - Has The Bull Case Changed?

Trulieve Cannabis (TRLV) issued 10 million shares worth $55.5 million in an ESOP-related offering, causing a 6.5% stock price increase. The company also authorized a $50 million share buyback program. Analysts project varying revenue and earnings forecasts for 2029, with some seeing significant upside and others a more pessimistic outlook. Q2 2026 sales declined year over year, and net loss widened, keeping margin trends and capital deployment in focus.

$ZIMMedAI 8/10

Dow, S&P 500, Nasdaq Futures Rise On AI, Fed Watch After Holiday Break: Why ZIM, AAPL, TCNNF, DIS Kept Traders On Edge Today

U.S. stock futures rose late Monday, with Nasdaq up 0.01%, S&P 500 up 0.1%, and Dow up 0.05%. Investors focused on AI disruption, Fed rate path, and inflation data. ZIM agreed to a $4.2B acquisition by Hapag-Lloyd at $35 per share. AAPL announced a March 4 event, potentially featuring new products. TCNNF and DIS also drew attention.

$TRLVMedAI 8/10

Trulieve Cannabis Q2 Earnings Call Highlights

Trulieve Cannabis reported Q2 revenue of $271 million, including $222 million medical-only revenue. Adjusted EBITDA was $98 million (36% margin). Operating cash flow was $53 million and free cash flow $32 million, with $325 million cash and $289 million debt. The company authorized a $50 million share repurchase program in June. It expects Q3 medical-only revenue comparable to $222 million and raised capex to $95 million.

$TRLVMedAI 8/10

Trulieve Reports Second Quarter 2026 Results

Trulieve Cannabis Corp. (NYSE: TRLV) reported Q2 2026 revenue of $271 million and 60% gross margin, with 94% of revenue from retail sales. GAAP net loss attributable to common shareholders was $406 million, including a $407 million impact from Harvest deconsolidation. Adjusted net income was $20 million. Cash flow from operations was $109 million and free cash flow $74 million for the first half. The company also announced a share repurchase program.

MedAI 8/10

Why is Trulieve Cannabis stock rallying today?

Trulieve Cannabis (TRLV) shares rose 5.6% premarket to $9.50 after it reported Q2 2026 results before the open. The quarter was the first full period under federal rescheduling of state-legal medical cannabis from Schedule I to III, removing 280E tax for qualifying operators, according to the DOJ and DEA. Analysts expected about $0.08 EPS on ~$272M revenue, and seven analysts rated TRLV Buy-equivalent with an average $18.71 target.

$TRLVMed

Trulieve Cannabis Corp. (TRLV): Completion of Acquisition or Disposition of Assets

Trulieve Cannabis Corp. (TRLV) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Trulieve Reports Second Quarter 2026 Results • Second quarter revenue of $271 million, with 60% gross margin • Cash flow from operations of $109 million and free cash flow of $74 million* in first half of 2026 • First U.S. Cannabis Company listed on New York Stock Ex